Not admitted · Third-party claim

“But I think we’re nearing a point where DBS is becoming more precise, and as soon as it’s there, it’s going to be much easier for all of you to program. You’re just going to have to look at the patient and their symptom-specific or brain-symptom-specific profile. And then it’s defined: the right dose, the right target. You don’t have to endlessly cycle through different settings. And that’s going to meaningfully improve access.”